ResMed Inc. released financial results for the first quarter of fiscal year 2027, which ended September 30, 2026. Revenue climbed 6% to $1.4 billion, propelled by sustained global demand for sleep and respiratory health solutions. GAAP diluted earnings per share rose 23% to $2.92, while non-GAAP diluted earnings per share increased 14% to $2.91.
The company returned more than $1.0 billion to shareholders during the quarter through share repurchases and dividends, funded by operating cash flows and proceeds from the divestiture of its MatrixCare business.
ResMed’s board of directors also declared a quarterly cash dividend of $0.66 per share. The dividend will be paid on December 17, 2026, to stockholders of record as of November 12, 2026. The ex-dividend date for both common stockholders and CHESS Depositary Interests holders is November 11, 2026. The company secured a waiver from the ASX’s settlement operating rules to defer processing conversions between its common stock and CDI registers from November 11 through November 12, 2026, inclusive.
During the quarter, ResMed completed the previously announced sale of the MatrixCare business. The company also introduced the AirTouch F40 in the U.S., the latest addition to its expanding portfolio of fabric CPAP masks.
Also Read
- McCullum Backs Brook’s Captaincy as England Concludes Pakistan Tri-Series
- Spain’s latest deadly train crash puts human error and systemic failure under scrutiny
- IDF Moves to Demolish Homes of Hebron Attackers Who Killed Two Soldiers
- Erin Patterson to die in prison after losing appeal against mushroom murder convictions
